GSTπ expression mediates dopaminergic neuron sensitivity in experimental parkinsonism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 6, 2007, Pages 1977-1982

  Smeyne, Michelle ^a   Boyd, Justin ^a   Shepherd, Kennie Raviie ^a   Jiao, Yun ^a   Pond, Brooks Barnes ^a   Hatler, Matthew ^a   Wolf, Roland ^b   Henderson, Colin ^b   Smeyne, Richard Jay ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Detoxification; Glutathione; Oxidative stress; Parkinson's disease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COMPLEMENTARY DNA; FREE RADICAL; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYDROXYL RADICAL; RNA; DOPAMINE; GLUTATHIONE TRANSFERASE P1; REACTIVE OXYGEN METABOLITE; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; NERVE CELL; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; GLUTATHIONE S-TRANSFERASE PI; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PARKINSONIAN DISORDERS; REACTIVE OXYGEN SPECIES; SUBSTANTIA NIGRA; XENOBIOTICS;

EID: 33846905913     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0610978104     Document Type: Article

References (47)

1. Salinas AE, Wong MG (1999) Curr Med Chem 6:279-309.
2. Townsend DM, Tew KD (2003) Oncogene 22:7369-7375.
3. Beiswanger CM, Diegmann MH, Novak RF, Philbert MA, Graessle TL, Reuhl KR, Lowndes HE (1995) Neurotoxicoiogy 16:425-440.
4. Awasthi YC, Sharma R, Singhal SS (1994) Int J Biochem 26:295-308.
5. Wang T, Arifoglu P, Ronai Z, Tew KD (2001) J Biol Chem 276:20999-21003.
6. Jenner P, Olanow CW (1998) Ann Neurol 44:S72-S84.
7. Smeyne RJ, Jackson-Lewis V (2005) Mol Brain Res 134:57-6.6.
8. Beal MF (2003) Ann NY Acad Sci 991:120-131.
9. Peng J, Andersen JK (2003) IUBMB Life 55:267-271.
10. Kaur D, Andersen J (2004) Ageing Res Rev 3:327-343.
11. Hamre K, Tharp R, Poon K, Xiong X, Smeyne RJ (1999) Brain Res 828:91-103.
12. Smeyne M, Jiao Y, Shepherd KR, Smeyne RJ (2005) Glia 52:144-152.
13. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, et al. (1999) EMBO J 18:1321-1334.
14. Smeyne M, Goloubeva O, Smeyne RJ (2001) Glia 74:73-80.
15. Ploemen JH, van Ommen B, van Bladeren PJ (1990) Biochem Pharmacol 40:1631-1635.
16. Colton CA, Pagan F, Snell J, Colton JS, Cummins A, Gilbert DL (1995) Exp Neurol 132:54-61.
17. Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ, Wolf CR (1998) Proc Natl Acad Sci USA 95:5275-5280.
18. Cook R, Lu L, Gu J, Williams RW, Smeyne RJ (2003) Mol Brain Res 110:279-288.
19. Jakoby WB (1978) Adv Enzymol Relat Areas Mol Biol 46:383-414.
20. Dringen R, Hamprecht B (1996) J Neurochem 67:1375-1382.
21. Wullner U, Loschmann PA, Schulz JB, Schmid A, Dringen R, Eblen F, Turski L, Klockgether T (1996) NeuroReport 7:921-923.
22. Toffa S, Kunikowska GM, Zeng BY, Jenner P, Marsden CD (1997) J Neural Transm 104:67-75.
23. Dringen R (2000) Prog Neurobiol 62:649-671.
24. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF (2000) J Neurosci 20:1-7.
25. Chinta SJ, Kumar JM, Zhang H, Forman HJ, Andersen JK (2006) Free Radical Biol Med 40:1557-1563.
26. Coles B, Wilson I, Wardman P, Hinson JA, Nelson SD, Ketterer B (1988) Arch Biochem Biophys 264:253-260.
27. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA (2002) Neurobiol Dis 10:119-127.
28. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Nat Neurosci 3:1301-1306.
29. Awasthi YC, Singh SV, Shen RS, Abell CW, Gessner W, Brossi A (1987) Neurosci Lett 81:159-164.
30. Bare S, Page G, Barrier L, Garreau L, Guilloteau D, Fauconneau B, Chalon S (2002) J Neurochem 80:365-374.
31. Staal RGW, Hogan KA, Liang CL, German DC, Sonsalla PK (2000) J Pharmacol Exp Ther 293:329-335.
32. Adler V, Pincus MR (2004) Ann Clin Lab Sci 34:35-46.
33. Faherty CJ, Smeyne RJ (2004) in Parkinson's Disease, eds Ebadi M, Pfeiffer RF (CRC, Boca Raton, FL), pp 523-535.
34. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couleur DG (1998) Lancet 352:1344-1346.
35. Kelada SN, Stapleton PL, Farin FM, Sammler TK, Eaton DL, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT, Jr, Checkoway H (2003) Neurosci Lett 337:5-8.
36. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ (2005) Proc Natl Acad Sci USA 102:8024-8029.
37. Usarek E, Gajewska B, Kazmierczak B, Kuzma M, Dziewulska D, Baranczyk-Kuzma A (2005) Neurochem Res 30:1003-1007.
38. Korell M, Tanner CM (2004) in Parkinson's Disease, eds Ebadi M, Pfeiffer RF (CRC, Boca Raton, FL), pp 39-50.
39. Pankratz N, Foroud T (2004) NeuroRx 1:235-242.
40. Gandhi S, Wood NW (2005) Hum Mol Genet 14:2749-2755.
41. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT (2002) J Neurosci 22:7006-7015.
42. Rice DS, Sheldon M, D'Arcangelo G, Nakajima K, Goldowitz D, Curran T (1998) Development (Cambridge, UK) 125:3719-3729.
43. Xu X, Stambrook PJ (1994) J Biol Chem 269:30268-30273.
44. Silver LM (1995) Mouse Genetics: Concepts and Applications (Oxford Univ Press, New York).
45. West MJ, Slomianka L, Gundersen HJ (1991) Anat Rec 231:482-497.
46. Fornai F, Alessandri MG, Torracca MT, Bassi L, Corsini GU (1997) J Pharmacol Exp Ther 283:100-107.
47. Acworth IN, Cunningham ML (1999) in Methods in Molecular Medicine, eds Harry J, Tilson HA (Humana, Totowa, NJ), Vol 22, pp 219-236.